Systemic juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritisand characterized by arthritis and many systemic features like fever, rash,hepatosplenomegaly, lymphadenopathy and serositis. Macrophage activationsyndrome is the most dreadful complication of systemic juvenile idiopathicarthritis and can cause mortality and morbidity if not recognized and treatedearly and aggressively.Hemophagocytic lymphohistiocytosis (HLH) is characterized by diminished orabsent activities of natural killer cells and cytotoxic T lymphocytes leadingto cytokine storm and uncontrolled activation of T cells and macrophages.Primary (familial) HLH is a group of autosomal recessive disorders causedby mutations in the perforin and other related genes and distinctive foronset during early infancy and high rate of mortality. Secondary HLH maybe caused by infectious, oncologic and rheumatologic disorders. The termPerforinopathy is used to describe cases with classical familial HLH and alsofor cases with familial HLH gene mutations but not following a classicalfamilial HLH course.Herein we report a case of chronic perforinopathy in which clinical symptomsstarted with systemic juvenile idiopathic arthritis and severe macrophageactivation syndrome that needed plasma exchange and extracorporeal membraneoxygenation during acute period and ongoing interleukin-1 blockage forsustained hyperferritinemia.
___
1. Benedetti FD, Schneider R. Systemic Juvenile Idiopathic Arthritis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR (eds). Textbook of Pediatric Rheumatology (7th ed). Philadelphia: Elsevier, 2016: 205-216.
2. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin N Am 2012; 59: 301-327.
3. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes Immune2012; 13: 289-298.
4. Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol 2015; 11: 1043-1053.
5. Celkan T, Berrak S, Kazanci E, et al. Malignancyassociated hemophagocytic lymphohistiocytosis in pediatric cases: A multicenter study from Turkey. Turk J Pediatr 2009; 51: 207-213.
6. Canna SW, Behrens EM. Making sense of the cytokine storm: A conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am 2012; 59: 329-344.
7. Voskoboinik I, Trapani JA. Perforinopathy: A spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol 2013; 4: 441.
8. Boom V, Anton J, Lahdenne P, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015; 13: 55.
9. Arceci RJ. Histiocytosis Syndromes. In: Lanzkowsky P (ed) Manual of Pediatric Hematology and Oncology (5th ed). Philadelphia: Elsevier, 2011: 567-598.
10. Vastert SJ, van Wijk R, D'Urbano LE, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010; 49: 441-449.
11. Albayrak M, Kaya Z, Yilmaz-Keskin E, Stadt UZ, Koçak U, Gürsel T. Fatal Epstein-Barr virus infection in a case of familial hemophagocytic lymphohistiocytosis with syntaxin-11 mutation. Turk J Pediatr 2009; 51: 371-374.
12. de Jager W, Vastert SJ, Beekman JM, et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 2782-2793.
13. Huasong Z, Ping W, Xiangyuan C, Yandan W. Clinical features and perforin A91V gene analysis in 31 patients with macrophage activation syndrome and systemic juvenile idiopathic arthritis in China. J Rheumatol 2013; 40: 1238-1239.
14. Mancebo E, Allende LM, Guzmán M, et al. Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection. Haematologica 2006; 91: 1257-1260.
15. Zur Stadt U, Beutel K, Weber B, Kabisch H, Schneppenheim R, Janka G. A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype. Blood 2004; 104: 1909.
16. Busiello R, Adriani M, Locatelli F, et al. Atypical features of familial hemophagocytic lymphohistiocytosis. Blood 2004; 103: 4610-4612.
17. Clementi R, Emmi L, Maccario R, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood 2002; 100: 2266-2267.
18. Okur H, Balta G, Akarsu N, et al. Clinical and molecular aspects of Turkish familial hemophagocytic lymphohistiocytosis patients with perforin mutations. Leuk Res 2008; 32: 972-975.
19. Okur H, Ünal Ş, Balta G, et al. The frequency of A91V in the perforin gene and the effect of tumor necrosis factor-α promoter polymorphism on acquired hemophagocytic lymphohistiocytosis. Turk J Haematol 2011; 28: 125-130.
20. Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, Aricò M. A single amino acid change A91V in perforin: A novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica 2005; 90: 697-698.
21. Trapani JA, Thia KY, Andrews M, et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology 2013; 2: e24185.
22. Chaudhry MS, Gilmour KC, House IG, et al. Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition. Oncoimmunology 2016; 5: e1179415.